echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Nat Biotech: New implantable stent more effective than CAR-T therapy

    Nat Biotech: New implantable stent more effective than CAR-T therapy

    • Last Update: 2022-04-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Researchers at the University of North Carolina at Chapel Hill and North Carolina State University have developed an implantable scaffold that releases CAR-T cells to attack tumors


    T cells are part of the immune system whose job is to recognize and destroy cells in the body that have been infected by invading pathogens


    "A major disadvantage of CAR-T cell therapy is that it is very expensive—hundreds of thousands of dollars per dose," said corresponding author Yevgeny Brudno


    "Many people are excluded from this treatment


    To address this challenge, the researchers developed an implantable scaffold called a multifunctional alginate scaffold for T cell engineering and release (MASTER)


    Before understanding the principle of MASTER, you must understand how CAR-T cells are generated


    First author Pritha Agarwalla, a postdoctoral researcher in the Joint Department of Biomedical Engineering, said: "Our MASTER technology transfers the tedious and time-consuming steps of activation, reprogramming and amplification to the patient


    MASTER is a biocompatible sponge-like material that looks a bit like cotton candy


    After implantation, the cell activation process continues


    "The MASTER material has properties similar to that of a sponge, allowing viruses and cells to bind tightly together, facilitating genetic reprogramming," Agarwalla said


    "When engineering this material, the key was to keep it dry and take up the mixture of T cells and virus," Brudno said.


    In these studies, the researchers used mice with lymphoma


    "Our technology is performing very well," Brudno said


    In addition, because cells are implanted within hours of isolation, fewer manipulations mean healthier cells


    "The end result was that mice treated with CAR-T cells through MASTER were much better at fighting tumors than mice treated with conventional CAR-T cells," Agarwalla said


    "MASTER technology is promising in liquid tumors such as lymphomas, but we're more eager to see its performance in solid tumors, including pancreatic and brain cancers," Brudno said


    “We are working with industry partners to commercialize this technology, but there is still a lot of work to be done before clinical application
    .
    Further research work is necessary before we start trying clinical trials in human patients, in animal models.
    to determine the safety and robustness of the technology
    .

    While it's impossible to estimate how much MASTER therapy might cost when it is eventually approved for clinical use, Brudno is optimistic that MASTER therapy will be significantly cheaper than existing CAR-T regimens
    .

    Original text retrieval

    Agarwalla, P.
    , Ogunnaike, EA, Ahn, S.
    et al.
    Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells.
    Nat Biotechnol (2022).
    https://doi.
    org/10.
    1038/s41587- 022-01245-x


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.